Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data.
暂无分享,去创建一个
Sabine Tejpar | Eva Budinska | Simona Rossi | Mauro Delorenzi | Vlad Popovici | Pratyaksha Wirapati | Tao Xie | Heather Estrella | M. Delorenzi | S. Rossi | A. Pavlícek | P. Wirapati | V. Popovici | S. Tejpar | F. Bosman | A. D. Di Narzo | Mao Mao | E. Martin | E. Budinská | A. Roth | P. Yan | Mao Mao | Pu Yan | Adam Pavlicek | Fred T Bosman | H. Estrella | Arnaud Roth | Antonio F Di Narzo | Eric Martin | Weinrich Scott | T. Xie | W. Scott
[1] I. Yang,et al. Molecular staging for survival prediction of colorectal cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] R. Greil,et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] S. Dudoit,et al. Stage II colon cancer prognosis prediction by tumor gene expression profiling. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Marek Skacel,et al. Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer. , 2008, The Journal of molecular diagnostics : JMD.
[5] T. Ørntoft,et al. Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer , 2009, Clinical Cancer Research.
[6] A. Nobel,et al. Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .
[7] M. Somerfield,et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Sridhar Ramaswamy,et al. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] R. Labianca,et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. , 2012, Journal of the National Cancer Institute.
[10] T. Yeatman,et al. Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer , 2011, Gut.
[11] L. Ein-Dor,et al. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[12] S. Paik,et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] L. V. van't Veer,et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] D. Kerr,et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Sabine Tejpar,et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] E. Van Cutsem,et al. Tissue Biomarker Development in a Multicentre Trial Context: a Feasibility Study on the PETACC3 Stage II and III Colon Cancer Adjuvant Treatment Trial , 2009, Clinical Cancer Research.
[17] D. Ransohoff. Rules of evidence for cancer molecular-marker discovery and validation , 2004, Nature Reviews Cancer.
[18] F. Harrell,et al. Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .
[19] T. Lumley,et al. Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker , 2000, Biometrics.
[20] N. Kasabov,et al. Multiple Gene Expression Classifiers from Different Array Platforms Predict Poor Prognosis of Colorectal Cancer , 2007, Clinical Cancer Research.
[21] Douglas G Altman,et al. Dichotomizing continuous predictors in multiple regression: a bad idea , 2006, Statistics in medicine.
[22] D. Sargent,et al. Revised TN categorization for colon cancer based on national survival outcomes data. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] J. Astola,et al. Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer. , 2005, Gastroenterology.
[24] R. Schilsky,et al. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] David C. Atkins,et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Sabine Tejpar,et al. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.